Experimental transplantation of neoplasms in laboratory animals for research purposes.
The transference of a part of or an entire liver from one human or animal to another.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transference of a kidney from one human or animal to another.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transference of a heart from one human or animal to another.
Transplantation of an individual's own tissue from one site to another site.
The transference of either one or both of the lungs from one human or animal to another.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transference of an organ between individuals of the same species or between individuals of different species.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
The transference of a pancreas from one human or animal to another.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
Elements of limited time intervals, contributing to particular results or situations.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Transference of fetal tissue between individuals of the same species or between individuals of different species.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
Neoplasms containing cyst-like formations or producing mucin or serum.
Transplantation between animals of different species.
The return of a sign, symptom, or disease after a remission.
Prospective patient listings for appointments or treatments.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Partial or total replacement of the CORNEA from one human or animal to another.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.
Tumors or cancer of the LIVER.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Tumors or cancer of the SKIN.
A dead body, usually a human body.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Pathological processes of the LIVER.
Transference of brain tissue, either from a fetus or from a born individual, between individuals of the same species or between individuals of different species.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
The transference between individuals of the entire face or major facial structures. In addition to the skin and cartilaginous tissue (CARTILAGE), it may include muscle and bone as well.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
The process by which organs are kept viable outside of the organism from which they were removed (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancers of the KIDNEY.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
A general term for various neoplastic diseases of the lymphoid tissue.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Tumors or cancer of the THYROID GLAND.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Disease having a short and relatively severe course.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Progenitor cells from which all blood cells derive.
The period following a surgical operation.
The transference of a complete HAND, as a composite of many tissue types, from one individual to another.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Tumors or cancer of the LUNG.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
DNA present in neoplastic tissue.
The procedure of removing TISSUES, organs, or specimens from DONORS for reuse, such as TRANSPLANTATION.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
Tumors or cancer of the PAROTID GLAND.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
A state of prolonged irreversible cessation of all brain activity, including lower brain stem function with the complete absence of voluntary movements, responses to stimuli, brain stem reflexes, and spontaneous respirations. Reversible conditions which mimic this clinical state (e.g., sedative overdose, hypothermia, etc.) are excluded prior to making the determination of brain death. (From Adams et al., Principles of Neurology, 6th ed, pp348-9)
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the APPENDIX.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Tumors or cancer of the ENDOCRINE GLANDS.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Tumors or cancer of the EYE.
Tumors or cancer of the BILE DUCTS.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Immunological rejection of leukemia cells following bone marrow transplantation.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
Excision of all or part of the liver. (Dorland, 28th ed)
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Tumors or cancer of the NOSE.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
The chilling of a tissue or organ during decreased BLOOD perfusion or in the absence of blood supply. Cold ischemia time during ORGAN TRANSPLANTATION begins when the organ is cooled with a cold perfusion solution after ORGAN PROCUREMENT surgery, and ends after the tissue reaches physiological temperature during implantation procedures.
Tumors or cancer of the SALIVARY GLANDS.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
Surgical union or shunt between ducts, tubes or vessels. It may be end-to-end, end-to-side, side-to-end, or side-to-side.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Disorders of the blood and blood forming tissues.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A benign epithelial tumor with a glandular organization.
Tumors or cancer of the SPLEEN.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Antibodies produced by a single clone of cells.
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
Tumors or cancer of the INTESTINES.
Providers of tissues for transplant to non-related individuals.
Tumors or cancer located in bone tissue or specific BONES.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Tumors or cancer of the UTERUS.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Classification of human colorectal adenocarcinoma cell lines. (1/10282)

Eleven human colorectal adenocarcinoma cell lines established in this laboratory were classified into three groups based on morphological features (light and electron microscopy), modal chromosome number, and ability to synthesize carcinoembryonic antigen (CEA). Group 1 cell lines contained both dedifferentiated and differentiating cells growing in tight clusters or islands of epithelium-like cells; their modal chromosome number was about 47, and they synthesized small to moderate amounts of CEA. Group 2 cell lines were more dedifferentiated, were hyperdiploid, and synthesized small amounts of CEA. Group 3 cell lines were morphologically similar to those of Group 1 by light microscopy. They differed ultrastructurally by containing microvesicular bodies; the modal chromosome number varied from hyperdiploid to hypertriploid or they had bimodal populations of hypodiploid and hypertriploid cells, and they synthesized relatively large amounts of CEA. No correlation could be found between Broder's grade or Duke's classification of the original tumor and modal chromosome number or ability to synthesize CEA. These findings support Nowell's hypothesis that the stem line is different for each solid tumor, which makes it difficult to relate chromosomal changes to the initiation of the neoplastic state.  (+info)

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats. (2/10282)

Three transitional cell carcinomas induced in Fischer 344 rats by a methylcholanthrene pellet or a foreign body inserted locally into the bladder have been serially transplanted in the syngeneic strain for up to 6.5 years. There have been no changes in the individual morphological characteristics of the tumors during this time. Cells cultured in vitro for varying numbers of passages reproduce regularly the morphology of each tumor when they are injected back into the animals and results from a microcytotoxicity assay for cellular immunity indicate that they retain a common, bladder tumor-specific antigen. These tumors are useful for research in turmo biology and are offered to other scientists seeking transplantable carcinomas for experimentation.  (+info)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (3/10282)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). (4/10282)

Fas ligand is a type II transmembrane protein which can induce apoptosis in Fas-expressing cells. Recent reports indicate that expression of FasL in transplanted cells may cause graft rejection and, on the other hand, tumor cells may lose their tumorigenicity when they are engineered to express FasL. These effects could be related to recruitment of neutrophils by FasL with activation of their cytotoxic machinery. In this study we investigated the antitumor effect of allogenic fibroblasts engineered to express FasL. Fibroblasts engineered to express FasL (PA317/FasL) did not exert toxic effects on transformed liver cell line (BNL) or colon cancer cell line (CT26) in vitro, but they could abrogate their tumorigenicity in vivo. Histological examination of the site of implantation of BNL cells mixed with PA317/FasL revealed massive infiltration of polymorphonuclear neutrophils and mononuclear cells. A specific immune protective effect was observed in animals primed with a mixture of BNL or CT26 and PA317/FasL cells. Rechallenge with tumor cells 14 or 100 days after priming resulted in protection of 100 or 50% of animals, respectively. This protective effect was due to CD8+ cells since depletion of CD8+ led to tumor formation. In addition, treatment of pre-established BNL tumors with a subcutaneous injection of BNL and PA317/FasL cell mixture at a distant site caused significant inhibition of tumor growth. These data demonstrate that allogenic cells engineered with FasL are able to abolish tumor growth and induce specific protective immunity when they are mixed with neoplastic cells.  (+info)

Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. (5/10282)

[18F]Fluorodeoxyglucose ([18F]FDG), a glucose analogue, has been widely used for tumor imaging. To investigate the mechanisms related to [18F]FDG uptake by tumors, an experiment involving nude mice was performed. METHODS: Human colon cancer cell lines SNU-C2A, SNU-C4 and SNU-C5 were transplanted to nude mice. Using immunohistochemical staining and Western blot, the expression of glucose transporter (Glut) isoforms (Glut-1 through -5) in xenografted tumors was analyzed. For the analysis of messenger ribonucleic acid (mRNA) expression, reverse-transcription polymerase chain reaction and Northern blot were used and the enzyme activity of hexokinase in cancer tissues was measured by continuous spectrophotometric rate determination. RESULTS: [18F]FDG uptake in SNU-C4 and SNU-C5 cells was higher than in normal colon cells. Among these cells and xenografted tumors, SNU-C5 showed the highest level of [18F]FDG uptake, followed by SNU-C4 and SNU-C2A. An immunostaining experiment showed intense staining of Glut-1 in SNU-C5 tumors but somewhat faint staining in SNU-C4. SNU-C5 tumors also showed positive staining with Glut-3, although this was not the case with SNU-C2A and SNU-C4. Western blot analysis showed the expression of Glut-1 and Glut-3 in all tumors. Experiments involving Northern blot analysis and reverse-transcription polymerase chain reaction confirmed the overexpression of Glut-1 mRNA in all tumors, with the highest level in SNU-C5. The level of Glut-3 mRNA was also elevated in SNU-C5 tumors but not in SNU-C2A and SNU-C4. The enzyme activity of hexokinase did not vary among different tumors. CONCLUSION: Gluts, especially Glut-1, are responsible for [18F]FDG uptake in a nude mouse model of colon cancer rather than hexokinase activity. Increased numbers of glucose transporters at the plasma membrane of cancer cells is attributed to an increased level of transcripts of glucose transporter genes and may be a cause of increased [18F]FDG uptake, at least in colon cancer tumors.  (+info)

99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. (6/10282)

Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino acid peptide with a wide range of biological activities. Recent reports suggest that VIP receptors are expressed on a variety of malignant tumor cells and that the receptor density is higher than for somatostatin. Our aims were to label VIP with 99mTc--a generator-produced, inexpensive radionuclide that possesses ideal characteristics for scintigraphic imaging--and to evaluate 99mTc-VIP for bioactivity and its ability to detect experimental tumors. METHODS: VIP28 was modified at the carboxy terminus by the addition of four amino acids that provided an N4 configuration for a strong chelation of 99mTc. To eliminate steric hindrance, 4-aminobutyric acid (Aba) was used as a spacer. VIP28 was labeled with 1251, which served as a control. Biological activity of the modified VIP28 agonist (TP3654) was examined in vitro using a cell-binding assay and an opossum internal anal sphincter (IAS) smooth muscle relaxivity assay. Tissue distribution studies were performed at 4 and 24 h after injection, and receptor-blocking assays were also performed in nude mice bearing human colorectal cancer LS174T. Blood clearance was examined in normal Sprague-Dawley rats. RESULTS: The yield of 99mTc-TP3654 was quantitative, and the yields of 125I-VIP and 1251-TP3654 were >90%. All in vitro data strongly suggested that the biological activity of 99mTc-TP3654 agonist was equivalent to that of VIP28. As the time after injection increased, radioactivity in all tissues decreased, except in the receptor-enriched tumor (P = 0.84) and in the lungs (P = 0.78). The tumor uptake (0.23 percentage injected dose per gram of tissue [%ID/g]) was several-fold higher than 125I-VIP (0.06 %ID/g) at 24 h after injection in the similar system. In mice treated with unlabeled VIP or TP3654, the uptake of 99mTc-TP3654 decreased in all VIP receptor-rich tissues except the kidneys. The blood clearance was biphasic; the alpha half-time was 5 min and the beta half-time was approximately 120 min. CONCLUSION: VIP28 was modified and successfully labeled with 99mTc. The results of all in vitro examinations indicated that the biological activity of TP3654 was equivalent to that of native VIP28 and tumor binding was receptor specific.  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (7/10282)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. (8/10282)

Interleukin 6 (IL-6) is a multifunctional cytokine. Recent reports suggest that circulating IL-6 secreted from tumour cells plays an important role in cancer-induced cachexia. Medroxyprogesterone acetate (MPA) has been used as an endocrine therapeutic agent for patients with breast cancer. It has been suggested that MPA decreases serum IL-6 levels and preserves the bodyweight of patients with advanced breast cancer. However, the mechanisms of action responsible for the anticachectic effect of MPA have not been elucidated. Therefore, the effects of MPA on IL-6 secretion were studied both in vitro and in vivo using a human breast cancer cell line, KPL-4, which secretes IL-6 into medium and induces cachexia when injected into female nude mice. MPA (10-1000 nM) dose-dependently decreased basal IL-6 secretion into medium, and also suppressed tumour necrosis factor (TNF-alpha)-induced IL-6 secretion. Both basal and TNF-alpha-induced IL-6 mRNA levels were dose-dependently lowered by MPA. Moreover, intramuscular injections of MPA (100 mg kg(-1) twice a week) into nude mice bearing KPL-4 transplanted tumours significantly decreased serum IL-6 levels without affecting tumour growth and preserved the bodyweight of recipient mice. These findings suggest that suppression of IL-6 secretion from tumour cells, at least in part, causes the anticachectic effect of MPA.  (+info)

Shapiro, W R.; Basler, G A.; and Posner, J B., Human brain tumor transplantation into nude mice. (1979). Subject Strain Bibliography 1979. 2465 ...
TY - JOUR. T1 - 1H-NMR relaxation times and water compartmentalization in experimental tumor models. AU - Braunschweiger, P. G.. AU - Schiffer, L. M.. AU - Furmanski, P.. PY - 1986. Y1 - 1986. N2 - The present studies were conduced with RIF-1, M5076 and Panc02 subcutaneous tumor models to assess the relationship between tissue-free water compartmentalization and observed tissue T1 and T2 changes at 10 MHz. Observed T1 was shown to correlate directly with total extracellular water and interstitial water volumes. T1 and T2 were also inversely related to intracellular water volumes. T1 and T2 decreases after dexamethasone treatment were, however, most closely correlated with changes in tumor extracellular water and not changes in cell or total water volumes. Studies to assess Gd-DTPA-dimeg dose dependent T1 and T2 modification in model serum protein solutions indicated that although the Gd concentration that reduced T2 by 50% was about 2.5 fold greater than that required to reduce T1 equally, the ...
Inoculation of mice from appropriate crosses with two strain A tumours and one dba (subline 2) tumour showed close linkage of such a gene with the locus for fused. With the A strain it was shown that the gene was identical with that for antigen II present in the erythrocytes. The gene is therefore labelled $H_{2}$. Of sixty-nine backcross mice tested, both serologically and by tumour inoculation, sixty-five gave concordant results, four discordant results. In general, it appears that serological tests are preferable to tumour inoculation in the identification of genotypes. On serological grounds it is suggested that the dba gene is an allele of the above and should be called $H_{2}{}^{d}$. It is possible that there is a long series of alleles at this locus. The indicated genotype of the strains used is as follows: $A,H_{2}H_{2}$; $dba,H_{2}{}^{d}H_{2}{}^{d}$; CBA, C57 and $P,h_{2}h_{2}$; $CA,Fu$ $h_{2}/fu$ $h_{2}$. Further tests may show differences in the $h_{2}$ allele in the last four ...
A test that detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from...
A new cancer therapy, called checkpoint blockade, has had some striking successes, but unfortunately it hasnt shown potential for treating the most lethal tumors. Now scientists are testing a way to spur checkpoint blockade into more potent action using nanoparticles.
TY - JOUR. T1 - Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice. T2 - Correlation of metastatic sites in mouse and individual patient donors. AU - Furukawa, Toshiharu. AU - Kubota, Tetsuro. AU - Watanabe, Masahiko. AU - Kitajima, Masaki. AU - Hoffman, Robert M.. PY - 1993/2/20. Y1 - 1993/2/20. N2 - Fresh surgical specimens derived from 36 patients with advanced stomach cancer were orthotopically transplanted in nude mice using histologically intact tissue. Twenty of 36 patient tumors gave rise to locally growing tumors in the mice. All 20 patients whose stomach tumors resulted in local growth in the nude mice had clinical lymph‐node involvement, whereas 8 of the other 16 patients whose tumors were rejected had lymph‐node involvement. There was a statistical correlation(p ,0.01) between local tumor growth in nude mice and clinical lymph‐node involvement. Of the 20 cases resulting in local growth in the nude mice, 5 had clinical liver ...
Purpose: Cultured tumor fragments from melanoma metastases have been used as a source of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy. The expansion of tumor-reactive CD8+ T cells with IL-2 in these early cultures is critical in generating clinically active TIL infusion products, with a population of activated 4-1BB CD8+ T cells recently found to constitute the majority of tumor-specific T cells. Experimental Design:We used an agonistic anti-4-1BB antibody added during the initial tumor fragment cultures to provide in situ 4-1BB co-stimulation. Results: Addition of an agonistic anti-4-1BB antibody could activate 4-1BB signaling within early cultured tumor fragments and accelerated the rate of memory CD8+ TIL outgrowth that were highly enriched for melanoma antigen specificity. This was associated with NFkappaB activation and the induction of T-cell survival and memory genes, as well as enhanced IL-2 responsiveness, in the CD8+ T cells in the fragments and emerging from the ...
BioAssay record AID 710427 submitted by ChEMBL: Binding affinity to TLR2 in human SU.86.86 cells xenografted in Harlan athymic nude mouse tumor assessed as increase in fluorescence at 100 nmol/kg, iv measured up to 24 hrs.
Apffel, C A. and Peters, J H., Successful heterotransplantation of l1210 mouse leukosis into un- treated adult hamsters. Abstr. (1968). Subject Strain Bibliography 1968. 45 ...
Figure 4. Treg lineage instability removes intratumor immune suppression. A and B, experiment schematic: tumors were isolated and dissociated, and 10,000 live tumor cells were then embedded along with all tumor-infiltrating cells (∼3-5 times tumor cell counts) in collagen-fibrin gel together with or without CTLs as described in Materials and Methods. After 24, 48, and 72 hours, gels were lysed and viable cells were cultured in a colony-forming assay. No killing would appear with 100+ colonies, and killing would show very few colonies. A, graphs show number of viable tumor cells recovered at indicated time points for IgG (left) and DTA-1 (middle) for total tumors alone (blue line) or with activated OT-1 T cells (red line). Right, rate of B16 cell killing by OT-1 CTL (killing constant k, as calculated in Materiala and Methods), of IgG (dark gray) and DTA-1 (white) tumors is shown compared with primary tissue culture B16 cells alone (light gray). B, viable tumor cells recovered from cultures of ...
Many cancer cell types, as well as their metastases, express high levels of CD44. Whereas some tumors, such as gliomas, exclusively display CD44s, other neoplasms, including brain metastases, gastrointestinal cancer, pancreatic adenocarcinoma, bladder cancer, uterine cervical cancer, breast cancer and non-Hodgkins lymphomas, additionally and sometimes preferentially express CD44 variants. Hence, CD44, particularly its variants, may be used as diagnostic or prognostic markers of at least some human malignant diseases. Furthermore, it has been demonstrated in animal models that upon transfection with CD44s, or CD44v cDNA, nonmetastatic tumor cells acquire metastatic potential. In addition, injection of reagents interfering with CD44-ligand interaction (e.g. CD44s- or CD44v-specific mAb) inhibit local tumor growth and metastatic spread in murine species. In this context, CD44 may confer a growth advantage on some neoplastic cells, and consequently could be used as a target for cancer therapy. The ...
I recently read with great interest, the opposing viewpoints on Is there enough benefit to justify sequencing all patients tumors?, published in JAMA Oncology (April 14, 2016). From the Yes side: sequencing technology provides invaluable intelligence to diagnose, treat, and defeat cancer (Universal Genomic Testing Needed to Win the War Against Cancer by Razelle Kurzrock, MD, and Vivek Subbiah, MD). From the No side: rigorously tested superiority and outcome data are lacking and the cost to patients is still prohibitive (No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing by Howard Jack West, MD). Both of these are compelling arguments, in spite of their contradictory nature, that deserve ongoing consideration in the oncology community. What we are increasingly coming to understand is that beyond a relatively small set of driver aberrations, whose testing and treatment are specified in standard treatment guidelines, there are a wealth of other molecular abnormalities in ...
Checkpoint blockade targeting PD-1/PD-L1 has clinical efficacy in a variety of tumor types, and has been shown to function through activation of T cells. However, PD-1 is also expressed on macrophages, prompting Gordon and colleagues to investigate the effects of PD-1 blockade on macrophages in the tumor microenvironment. Fluorescence-activated cell sorting of cells from syngeneic colon cancer models revealed that approximately 50% of tumor-associated macrophages (TAM) expressed surface PD-1. In contrast, no circulating monocytes or splenic macrophages had detectable PD-1 expression. The majority of PD-1+ TAMs exhibited an M2-like surface profile, suggesting a protumor phenotypes, whereas the PD-1− TAMs were often M1-like, indicative of an inflammatory phenotype. The PD-1+ TAM population emerged approximately 2 weeks after tumor engraftment, and PD-1 expression increased over time. Consistent with these findings, TAMs from human colorectal tumors exhibited high but variable expression of PD-1, ...
Maloney began by explaining that CAR-T cells produced from distinct T-cell subsets differ in potency. NSG mice bearing Raji tumors (0.5x10 6tumor cell inoculation; day 0) were treated with human CAR-T cells manufactured from distinct T-cell subsets (on day 7). CAR-T cells produced from CD8 +T CMcells were highly potent ( Sommermeyer et al.2015).. Engineering selected T-cell subsets could enhance potency and allow delivery of the same cell product in all patients, potentially providing more uniform data on dose response and toxicity.. Pre-clinical studies have established that a defined composition of CD8 +T CMderived and CD4 +derived CAR T-cells provides optimal potency.. ...
Our groups cover a broad spectrum of interdisciplinary expertise, from mathematical modeling, cell biology, biochemistry, structural, developmental and stem cell biology to immunology, experimental tumor models and clinical oncology.. We place special emphasis on the translation of scientific findings into the clinics for the development of novel therapies, including drugs, gene and cell therapy approaches, and collaborate closely with clinically oriented groups at the Charité - Universitätsmedizin Berlin.. ...
Murine leukemia L1210 has been treated with cyclophosphamide and 4 sublines have been developed from the tumor cells surviving drug therapy. Biologic studies have demonstrated a marked alteration of virulence compared to the parent tumor and striking cytogenetic modifications have been found to exist. Serial examinations over an interval of 22 weekly transplant generations have demonstrated a biologic and cytogenetic instability characterized by, generally, a tendency for return toward control values.. ...
Carcinoembryonic antigen (CEA) was purified from GW-39 human tumor xenografts in hamsters by immunoaffinity chromatography. Binding of the antigen to immobilized monoclonal antibody provided a high degree of purification of CEA in a single step. A recovery of 79% and a 750-fold purification were obtained. The purified CEA has a molecular size of 180 kilodaltons, an isoelectric point of 4.4, and a specific activity of 0.94. About 73% of the radiolabeled GW-39 CEA reacted with goat anti-CEA serum ...
Original FAG 546238A bearing. BIS 540626AA.J30NF Bearing BIS 540733BA Bearing BIS 540733CA Bearing BIS 540805A Bearing BIS 541019.S3 Bearing BIS 541332A.K158X4 *4 Bearing BIS 541521C Bearing BIS 542186A Bearing BIS 543185A Bearing BIS 543187A Bearing BIS 54322MP Bearing BIS 543307A.K158X12 *12 Bearing BIS 544307D Bearing BIS 544873TVP Bearing BIS 545312A Bearing BIS 545495AD Bearing BIS 546065.C3.L145 Bearing BIS 546238A ...
nude mouse definition: a mouse with an inherited problem that prevents all of them from developing locks also stops them from immunologically rejecting personal cells and tissues; popular in preclinical…
TY - JOUR. T1 - Decreased macrophage‐mediated cytotoxicity in mammary‐tumor‐bearing mice is related to alteration of nitric‐oxide production and/or release. AU - Sotomayor, Eduardo M.. AU - Dinapoli, Michael R.. AU - Calderón, Cesar. AU - Colsky, Arthur. AU - Fu, Yang‐Xin ‐X. AU - Lopez, Diana M.. PY - 1995/3/3. Y1 - 1995/3/3. N2 - Peritoneal‐exudate macrophages (PEM) from mammarytumor‐bearing mice have impaired cytotoxic activity against syngeneic and allogeneic tumor targets. The ability of PEM from normal and tumor‐bearing mice to bind tumor targets was found to be similar in the presence or the absence of surrogate receptors, which enhanced the binding but not the killing of tumor targets by PEM from tumor‐bearing mice, suggesting that other mechanisms are involved in their impaired cytolytic activity. Soluble and membrane‐bound TNF‐α, as well as H2O2, were found in higher amounts in PEM from tumor bearers upon stimulation with LPS, as compared with PEM from normal ...
The ability to generate a large number of tumor-reactive T lymphocytes is the most critical requirement for adoptive immunotherapy. Our laboratory has previously demonstrated that cells from tumor-draining lymph nodes (LNs) are an excellent source of tumor-reactive T lymphocytes. After activation with anti-CD3, these cells readily proliferate in low concentrations of interleukin 2 and acquire effector functions. The adoptive transfer of these cells is capable of mediating the regression of tumors established in the lung as well as in the brain. Here, we analyzed several adhesion molecules on the tumor-draining LN T cells and separated them based on l-selectin expression. The homing receptor l-selectin mediates adhesion to the luminal surface of specialized high endothelial venules, thus regulating lymphocyte recirculation through peripheral LNs. In response to progressive tumor growth, a small population of draining LN T cells down-regulated l-selectin and increased the expression of CD44 and ...
Summary Simian virus 40 (SV40)-transformed cells express the SV40-specific tumour transplantation antigen (TSTA) on the cell surface and the SV40-coded tumour antigen in their nuclei. TSTA is defined by SV40-specific transplantation immunity, whereas T-antigen (T-Ag) can be detected serologically by indirect immunofluorescence. Both antigens, however, are derived from the A gene of SV40. We therefore analysed SV40-transformed cells for the presence of serologically detectable T-Ag-related molecules. Such antigens could not be detected on the surface of living SV40-transformed cells in monolayers. However, after a short formaldehyde fixation it was possible to stain the cell surfaces of SV40-transformed cells with sera from rabbits immunized with purified SDS-denatured T-Ag, but not with sera from hamsters bearing SV40-induced tumours. T-Ag-related antigens could be detected with both types of antisera by applying a more sensitive 125I-protein A assay. The T-Ag specificity of the binding of hamster SV40
It is well understood by oncologists that tumor growth and metastasis depend on changes in the tumor microenvironment or stroma. Stromal changes have been the focus of numerous research publications and have led to insights in both tumor development and promising new avenues for treatment [1-7].. In order to study molecular changes in stroma from tissue samples, it is necessary to separate tumor tissue from stromal tissue. Without this separation we have sample heterogeneity, which is well known to severely limit the conclusions that can be made about the specificity of molecular changes and their biological causes [5, 7-11]. This separation can be difficult in contexts where tumors are small or not well differentiated. For example, in mouse tumor xenograft models, human cancer cells are grown in immune-suppressed mice [12-15]. These models are popular in oncologic research for studying mechanisms of tumor growth and metastasis, as well as drug response. In such studies, secondary tumors (at ...
Background: The reasons why the lungs are preferential metastatic targets for some human cancers are unknown.. Aims: To unravel the mechanism of tumor pneumotropism.. Methods: Several mouse and human tumor cell lines were genotyped for key oncogenes and tumor suppressors. Their potential for spontaneous lung metastasis was assessed by subcutaneous inoculation into receptive host mice. Mutant oncogenes were silenced via shRNA or introduced using relevant expression vectors. Chemokine signaling was studied using microarray, qPCR, ELISA and immunobloting and was abrogated using chemokine receptor-deficient mice.. Results: Spontaneous lung metastasis co-segregated with the presence of NRAS mutations detected in 3 of 11 cell lines studied. The expected frequency of NRAS mutations based on COSMIC (http://cancer.sanger.ac.uk/cosmic/) was tightly correlated (P=0.0000054, R2=0.652) with lung metastasis at necropsy in 3827 patients with various cancers (Disibio, G. et al. Arch Pathol Lab Med ...
A competent and expanding vascular supply is a necessary component of the progressive growth of solid tumors because cells in solid tumors, like normal tissue, must receive oxygen and other nutrients to survive and grow (17) . The connection between oxygen supply and tumor growth was first made in the 1950s by radiobiologists who were aware of oxygen as a radiosensitizer and the fact that hypoxic cells in tumors are resistant to radiation therapy (18) . Histological analyses of human and rodent tumors performed by Thomlinson and Gray (18) were the first studies to suggest that regions of viable cells exist close to tumor blood vessels and that these walls or cords of viable tumor cells correspond in thickness to the distance that oxygen can diffuse (1-2 mm3). The tumor cord model implied that hypoxic cells exist in a state of oxygen and nutrient starvation at the limits of the diffusion range of oxygen, and it was hypothesized that tumor cells could proliferate and grow only if they were close ...
TY - JOUR. T1 - Abdominal-wall tumor implantation after laparoscopy for malignant conditions. AU - Childers, Joel M.. AU - Aqua, Keith A.. AU - Surwit, Earl A.. AU - Hallum, Alton V.. AU - Hatch, Kenneth D.. PY - 1994/11. Y1 - 1994/11. N2 - Objective: To determine the incidence of abdominal-wall tumor implantation after laparoscopic procedures in patients with known malignancies. Methods: We reviewed 557 laparoscopic procedures performed by the Gynecologic Oncology Service between November 1990 and February 1994. In 105 procedures, malignancy was documented cytologically or histologically, 88 with intraperitoneal disease and 17 with retroperitoneal disease. Ovarian cancer represented 80% (70 of 88) of the procedures with intraperitoneal malignancy, and the remaining cases consisted of carcinoma of the fallopian tube (two), endometrium (11), cervix (one), breast (three), and stomach (one). Histologically, ovarian carcinomas ranged from low malignant potential to poorly differentiated. Among 88 ...
Gd-albumin is efficiently accumulated in SCC transplants. MRI with low loaded Gd-albumin may offer relevant opportunities for recognizing tumors sensitive to a therapy with cyostic drug-labeled albumins.
Animal models for human tumor xenografts are used for the study of biology and treatment of human cancer. The aim of this study was to develop a model for long-term tumor observations with the...
Note: This cell line was derived from a 4th passage nude mouse xenograft of tumor fragments obtained from a patient prior to therapy. This cell line is a pseudodiploid human cell line an and has a high concentration of receptors for EGF. This cell line has lost both chromosomes 8 and 11 while SNU-C2A has lost only chromosome 11. Penicillin-streptomycin were added to culture media (final concentration, 100 U/mL ...
PhD Project - Exploring the similarities between neointimal formation after vascular injury and tumour growth at University of Bristol, listed on FindAPhD.com
Cell-line tumor. Huh-7-GFP cells (2×106) in 0.1 ml phosphate-buffered saline (PBS) were initially subcutaneously injected in the shoulder of nude mice. Resulting tumors were harvested and sectioned into small pieces for sutureless SOI to the liver.. Patient-derived tumor. A colon-cancer liver metastasis from a human patient was previously surgically obtained under standard sterile conditions at the UCSD Thornton hospital under UCSD IRB protocol 140046. Informed patient consent to utilize the tumor tissue for research was obtained prior to surgical resection (Figure 1A). Fresh tumor fragments were subcutaneously implanted in nude mice (Figure 1B). Once tumor growth was established subcutaneously, tumors were harvested and sectioned into small pieces for sutureless SOI to the liver (Figure 1C).. Sutureless SOI to the liver. Nude mice (n=10) were injected intra-muscularly with a ketamine solution (0.02 mL) for anesthesia prior to all procedures. The entire abdomen was sterilized with a 70% ethanol ...
OUTLINE: Previously collected breast tumor fragments are implanted into the renal capsule site of SCID mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics.. Patients medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment. ...
OUTLINE: Previously collected breast tumor fragments are implanted into the renal capsule site of SCID mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics.. Patients medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment. ...
Fingerprint Dive into the research topics of Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. Together they form a unique fingerprint. ...
Abstract. Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants and metastasis. While former studies have indicated that T-cell dependent processes mediate CR in hosts bearing immunogenic small tumors, the most universal manifestation of CR induced by immunogenic and non-immunogenic large tumors had been associated with an antitumor serum factor that remained an enigma for many years. In a recent paper, we identified that elusive factor(s) as an equi-molar mixture of meta-tyrosine and ortho-tyrosine, two isomers of tyrosine that are not present in normal proteins and that proved to be responsible for 90% and 10%, respectively, of the total serum anti-tumor activity. In this work, we have extended our previous findings demonstrating that a periodic intravenous administration of meta-tyrosine induced a dramatic reduction of lung and hepatic metastases generated in mice bearing two different metastatic murine tumors ...
Includes syngeneic models, human tumor xenograft models, orthotopic models, metastatic models, transgenic models, and gene knockout models Provides
Time-lapse movie of a human tumor fragment grown in Matrigel that was freed and reembedded in collagen I. Images collected every 15 minutes and bar i...
Annibale Carracci Fine Art Open Edition Gicl e:A Male Nude Seated with His Back Turned Artist: Annibale Carracci Title: A Male Nude Seated with His Back Turned Size: 30 x 19.9 Edition: Open Edition Medium: Fine Art Giclee on Paper ...
A newly funded TFRI dream team plans to tackle the most lethal and aggressive brain tumour that occurs in adults by focusing not on the original tumour, but on the relapsed cancer. &ldqu... Read More ...
Original TIMKEN 280RJ92 bearing. Bearing Links. SKF NKX40 bearing; TIMKEN 386A/384ED X1S-386A bearing; NSK QJ206 bearing; NTN 32018X bearing; KOYO 7018B bearing; IKO NA4852 bearing; NTN 2RNU2231 bearing; Timken 280RJ92 bearing; FAG Z-565666.ZL-K-C5 bearing; NTN M757448D/M757410/M757410D bearing
Original FAG 23030-E1A-K-M H3030 bearing. NTN EE221027D/221575/221576D bearing FAG 23030-E1A-K-M H3030 bearing TIMKEN 95500/95925 bearing SKF WBB1-8708-2RZ bearing NACHI 51126 bearing NTN 51420 bearing NTN 6011NR bearing INA BXRE004 bearing FAG 23936-S-MB bearing TIMKEN 835/834D X1S-835 bearing ...
Original KOYO 51280 bearing. INA GG 51280 Bearing INA B66 Bearing INA NK73/35 Bearing INA NK73/35 Bearing INA RUS 26126 Gr 4 Bearing INA PR14089.G...
I will introduce some KOYO bearings to you in this article,if you are in need of any of the below listed bearings,please send your valued inquiry to us.At the moment .... ...
Concomitant immunity is a phenomenon in which a tumour-bearing host is resistant to the growth of an implanted secondary tumour. Metastases are considered to be secondary tumours that develop spontaneously during primary tumour growth, suggesting the involvement of concomitant immunity in controlling the rise of metastases. It has been demonstrated that B-1 cells, a subset of B-lymphocytes found predominantly in pleural and peritoneal cavities, not only increase the metastatic development of murine melanoma B16F10, but also are capable of differentiating into mononuclear phagocytes, modulating inflammatory responses in wound healing, in oral tolerance and in Paracoccidiose brasiliensis infections. Here, we studied B-1 cells participation in concomitant immunity during Ehrlich tumour progression. Our results show that B-1 cells obtained from BALB/c mice previously injected with Ehrlich tumour in the footpad were able to protect BALB/c and BALB/Xid mice against Ehrlich tumour challenge. in ...
TY - JOUR. T1 - Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. AU - Opperman, Khatora S.. AU - Vandyke, Kate. AU - Clark, Kimberley C.. AU - Coulter, Elizabeth A.. AU - Hewett, Duncan R.. AU - Mrozik, Krzysztof M.. AU - Schwarz, Nisha. AU - Evdokiou, Andreas. AU - Croucher, Peter I.. AU - Psaltis, Peter. AU - Noll, Jacqueline E.. AU - Zannettino, Andrew. PY - 2019/8/1. Y1 - 2019/8/1. N2 - Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment. The bone marrow is comprised of numerous cells of mesenchymal and hemopoietic origin. Of these, macrophages have been implicated to play a role in myeloma disease progression, angiogenesis, and drug resistance; however, the role of macrophages in myeloma disease establishment remains unknown. In this study, the antimyeloma efficacy of clodronate-liposome treatment, which globally and transiently depletes macrophages, was evaluated in the ...
Looking for online definition of Athymic nude mouse in the Medical Dictionary? Athymic nude mouse explanation free. What is Athymic nude mouse? Meaning of Athymic nude mouse medical term. What does Athymic nude mouse mean?
Purpose: The avascular cornea is predestined to study neovascular responses. First experiences with this model date back to 1972, when Gimbrone et al heterotopically implanted tumor fragments in rabbit corneal pockets. Different assays in rabbit, rat, and mouse corneas have since been published including placement of (anti-)angiogenic growth factor releasing pellets or proangiogenic corneal sutures. Using murine corneas is surgically more intricate but advantageous due to the well-defined genetic background and availability of genetically modified animals. In mice, so far tumor-associated angiogenesis has been studied by inserting pre-grown tumor fragments into corneal pockets. Here we describe an alternative approach, where a suspension of cultured tumor cells is directly injected into the corneal stroma.. Methods: One µl of B16F10 melanoma cells suspended in PBS (100.000 cells/µl) and pre-stained with FITC+ CellTracker Green was injected into the paracentral corneal stroma of C57Bl/6 mice ...
TY - JOUR. T1 - Comparison of L bleomycin prepared by two methods. T2 - Stability and pharmacokinetics in tumor bearing mice. AU - Krohn, K. A.. AU - Meyers, J.. AU - Denardo, Gerald L. PY - 1977. Y1 - 1977. UR - http://www.scopus.com/inward/record.url?scp=0017623084&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0017623084&partnerID=8YFLogxK. M3 - Article. C2 - 63131. AN - SCOPUS:0017623084. VL - 122. SP - 179. EP - 182. JO - Radiology. JF - Radiology. SN - 0033-8419. IS - 1. ER - ...
TY - JOUR. T1 - Protective immunity induced by B7.1+IL-12 transfected tumor cells is abrogated by tumor growth in an immune privileged site. AU - Chen, P. W.. AU - Uno, T.. AU - Geer, D. G.. AU - Podack, E. R.. AU - Ksander, B. R.. PY - 1996/12/1. Y1 - 1996/12/1. N2 - Mice immunized with B7.1+IL-12 transfected tumor cells possess systemic anti-tumor immunity that protects mice from a second subcutaneous tumor challenge of untransfected cells. This study determines if these immunized mice are protected from a second tumor challenge delivered to an immunologically privileged site. Our previous results indicated that tumors growing within the immunologically privileged anterior chamber of the eye (AC) of naive mice induce systemic T cell tolerance. In these experiments we determined if tolerance could be imposed after mice were previously sensitized. DBA/2 mice were given a subcutaneous immunization with 1 × 106 P815 B7.1+IL-12 cells. One month later, mice received a second tumor challenge of ...
A two-stage modification of the leucocyte adherence inhibition (LAI) test is described, which quantitates cell-mediated immunity (CMI) in vitro with 0.5-ml samples of blood from mice exposed to methylcholanthrene-induced tumors. The total blood cells are washed and incubated for 30 min with tumor antigen, then centrifuged, and the supernatant assayed in the LAI test with normal peritoneal cells. The first stage of the reaction depends on the rapid formation of a soluble mediator which appears to be a lymphokine. By this method, the daily changes in specific CMI were followed in individual mice after syngeneic tumor transplantation ...
This is one of 14 colorectal carcinoma cell lines derived by J.G. Park and associates during the years 1982 through 1985. The line was obtained from a fourth passage nude mouse xenograft of tumor fragments obtained from a patient prior to therapy (see also ATCC CCL-250.1 which was derived from the third nude mouse passage).
In control arm, the tumor grew the fastest within the first couple weeks. As the tumor enlarged, we noticed a decline in growth rate of these tumors. In the control arm, the tumor growth rate was significantly higher in the first 15 days compared to the second 15 days. The tumor volume doubling time changed from 103 h in the first 15 days to 144 h in the second 15 days (P , 0.01). However, in the 2 mg T and 5 mg T arms, the opposite results were found. The data demonstrated that in 2 mg T and 5 mg T arms, the tumor growth rate was significantly lower in the first 15 days compared to the second 15 days, (184 h vs 133 h in 2 mg T arm, P , 0.05, 206 h vs 140 h in 5 mg T arm, P , 0.01). When comparing the growth rates of the control arm and the 2 mg T and 5 mg T arms in the first 15 days, the growth rates were much higher in the control arm (P , 0.01). However, in the second 15 days there was no significant difference in tumor growth rates in the control arm, 2 mg T arm, and 5 mg T arms (Fig. 4). ...
Tumors adapt to an unfavorable microenvironment by controlling the balance between cell proliferation and cell motility, but the regulators of this process are largely unknown. Here, we show that an alternatively spliced isoform of syntaphilin (SNPH), a cytoskeletal regulator of mitochondrial movements in neurons, is directed to mitochondria of tumor cells. Mitochondrial SNPH buffers oxidative stress and maintains complex II-dependent bioenergetics, sustaining local tumor growth while restricting mitochondrial redistribution to the cortical cytoskeleton and tumor cell motility. Conversely, introduction of stress stimuli to the microenvironment, including hypoxia, acutely lowered SNPH levels, resulting in bioenergetics defects and increased superoxide production. In turn, this suppressed tumor cell proliferation but increased tumor cell invasion via greater mitochondrial trafficking to the cortical cytoskeleton. Loss of SNPH or expression of an SNPH mutant lacking the mitochondrial localization ...
Tumors adapt to an unfavorable microenvironment by controlling the balance between cell proliferation and cell motility, but the regulators of this process are largely unknown. Here, we show that an alternatively spliced isoform of syntaphilin (SNPH), a cytoskeletal regulator of mitochondrial movements in neurons, is directed to mitochondria of tumor cells. Mitochondrial SNPH buffers oxidative stress and maintains complex II-dependent bioenergetics, sustaining local tumor growth while restricting mitochondrial redistribution to the cortical cytoskeleton and tumor cell motility. Conversely, introduction of stress stimuli to the microenvironment, including hypoxia, acutely lowered SNPH levels, resulting in bioenergetics defects and increased superoxide production. In turn, this suppressed tumor cell proliferation but increased tumor cell invasion via greater mitochondrial trafficking to the cortical cytoskeleton. Loss of SNPH or expression of an SNPH mutant lacking the mitochondrial localization ...
Adoptive cell transfer of tumor infiltrating lymphocytes has shown clinical efficacy in the treatment of melanoma and is now also being explored in other tumor types. Generation of sufficient numbers of effector T cells requires extensive ex vivo expansion, often at the cost of T cell differentiation and potency. For the past 20 years, IL-2 has been the key cytokine applied in the expansion of TIL for ACT. However, the use of IL-2 has also led to collateral expansion of regulatory T cells (Tregs) and progressive T cell differentiation, factors known to limit in vivo persistence and activity of transferred TIL. The use of alternative T cell growth factors is therefore warranted. Here, we have compared the effects of IL-2, -15 and −21 cytokines on the expansion and activation of TIL from single-cell suspensions of non-small cell lung cancer, ovarian cancer and melanoma. We applied the K562-based artificial APC (aAPC) platform for the direct and rapid expansion of tumor infiltrating lymphocytes isolated
Consistent with previous observations, c-Met Inhibitors staining exposed substantial regions of hemorrhagic necrosis devoid of CD31 staining along with viable tumor cells and CD31 blood vessels in the tumor rim. Interestingly, CD31 immunostained sections of orthotopic MCA tumors showed a really selective vascular response to DMXAA with intact vasculature noticeable in the neighboring muscle tissue.. Evaluation of R1 values of muscle tissue had been consistent with this observation and showed no statistically important big difference amongst handle and treatment method groups. Ultimately, we determined if the differential vascular response to DMXAA among ectopic and orthotopic MCA tumors correlated with intratumoral levels of TNF, a principal cytokine concerned in antivascular activity of DMXAA. Differences in intratumoral VEGF ranges have been also analyzed. As proven in Fig. 5A, untreated handle MCA tumors established at ectopic and orthotopic tissue sites showed very reduced amounts of TNF, ...
LY294002 price The sole reproducible distinction among wild variety and NG2 null specimens was the lowered num ber of lesions obvious at early time points in the absence of NG2, reinforcing the conclusions acquired from your total mount staining. Progression of transplanted mammary tumors Donor MMTV PyMT tumor fragments were transplanted into mammary extra fat pad web sites in 4 month old female wild sort and NG2 null mice that didnt carry the MMTV PyMT transgene. In wild style mice, 50% of transplantation web-sites had detectable tumors at 40 days post implantation. In NG2 null mice, the time for 50% incidence was extended to 80 days. Comparable outcomes had been obtained in a 2nd experiment using two month previous recipient females. These changes in tumor latency concerning wild kind and NG2 null mice therefore mimic the differences in latency seen with spontaneous mammary tumor advancement. Progression of mammary tumors from cell lines The Py230 and Py8119 cell lines were the two derived ...
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.. ...
www.MOLUNA.de Systems Biology of Tumor Dormancy [4197128] - This volume is based on the Workshop on Systems Biology of Tumor Dormancy meeting, held July 25th to July 28th, 2011. The first annual CCSB workshop brought together biologists, clinicians, mathematicians, and computer scientists to discuss various aspects of tumor dormancy and develop novel mathematical/computational models with the keynote speakers.
MSpace maintenance is scheduled to be performed between 9:00AM and 12:00PM CST on Thursday Jan 23, 2020. Access will be unavailable intermittently during that time. Please plan your submissions accordingly. Any in-progress submissions should be saved before the maintenance period.. ...
The majority of in vivo models of metastasis determine the effect of experimental conditions (usually via knock-out mice) by relying on the end point of secondary tumor formation at a distal site (14). However, the steps occurring between tumor cell injection and metastatic tumor formation are effectively shrouded in these models (15). Despite advances in imaging to monitor these processes, a crucial step of metastasis-the invasion and colonization of cancer cells upon extravasation-remains an elusive target. This study describes a three-dimensional culture system developed to model this phase in vitro and establishes the efficacy of this novel system by demonstrating that cells from disparate phases of melanoma invade the matrix in a manner proportional to their known metastatic capabilities. Specifically, the highly metastatic C8161.9 stayed true to its documented in vivo behavior (21), ferociously staking claim to much of the surrounding matrix (Fig. 1A-C). The sporadically metastatic M14 ...
Cancer is a class of diseases in which a group of cells displays uncontrolled growth and invasion that destroys adjacent tissues, and sometimes send metastasis to other locations in the body. When one is interested in cancer research, mice will be the preferred animal. Murine models of cancer include transplantable models, spontaneous and autochthonous models, human tumor xenografts, orthotopic models, models of metastasis and transgenic tumor models.
PDT in tumor-bearing mice. (a) 4T1 cells were injected subcutaneously in two separate locations on the back of BALB/c mice. After tumors were established (marke
Original NTN 60/1060 bearing. Bearing Links. FAG NU213-E-TVP2 bearing; NSK 6210NR bearing; KOYO N336 bearing; NSK 45BNR20SV1V bearing; KOYO 234418B bearing; NTN 60/1060 bearing; TIMKEN 581/572-B bearing; SKF S7020CD/HCP4A bearing; TIMKEN G1100KRR bearing; TIMKEN 5314KG bearing
A xenograft is cells or sections of tissue that are removed from one species and grafted onto another species. The main reason for...
蘇松濤報導】 據2021年Pinterest Predicts最新報告,現代人對社群修圖美學逐漸厭倦,反思生活中的真實性與對建構肌膚健康的基本要求。全球第一美容儀霸主Nu.... ...
EMH in the lymph nodes is usually associated with underlying hematopoietic neoplasms. Myeloproliferative neoplasms (MPNs) tend ... This includes transplantation, hepatic tumors, hepatic disorders, or sepsis. Hepatoblastoma, adenomas and hepatocellular ... para-nasal sinuses and numerous types of benign/malignant neoplasms. The most common sites of EMH associated with neoplastic ... "Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation". ...
Reparative surgery 120.6-129.8.............................Transplantation of organs, tissues, etc. 130 ... Neoplasms. Tumors. Oncology 680-688...................................Diseases of the locomotor system (Surgical treatment) 701 ... Neoplasms. Tumors. Oncology Including cancer and carcinogens 306-320.5................................Tuberculosis 321-571 ...
"The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation". N. Engl. J. Med. 332 (1 ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term neoplasm is a synonym of tumor. Neoplasia denotes the process of the formation of neoplasms/tumors, and the process is ... The process that occurs to form or produce a neoplasm is called neoplasia. The growth of a neoplasm is uncoordinated with that ...
Hematopoietic stem cell Hematopoietic stem cell transplantation Hematology Myelodysplastic syndrome Myeloproliferative neoplasm ... It has been shown that patients with CHIP who receive autologous stem cell transplantation (ASCT) as part of their treatment ... The poorer prognosis for these patients is due to both an increase in subsequent therapy-related myeloid neoplasms and ... "Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma". Journal of ...
He followed several alternative treatments, such as high vitamin C doses or neoplasm treatment at the Burzynski Clinic in ... Finally, he underwent conventional treatments of chemotherapy and bone marrow transplantation. He was under quarantine in his ...
Gadalla's work focuses on severe aplastic anemia and myeloid neoplasms with a goal of identifying biomarkers that can guide ... She also researches molecular predictors of outcomes after hematopoietic cell transplantation. ... is a physician-scientist and cancer epidemiologist who researches cancer biomarkers and hematopoietic stem cell transplantation ...
... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... This patient achieved a complete hematological response and was then given a hematopoietic stem cell transplantation. The ... Like the latter neoplasm, hematologic neoplasms cause by ETV6-JAK2 and BCR-JAK2 are aggressive and progress rapidly. Too few ... A classic example of such a disease is chronic myelogenous leukemia, a neoplasm commonly caused by a mutation that creates the ...
... myeloproliferative neoplasms, mast cell diseases and stem cell transplantation. In the past, Turner was the medical director of ...
Hematopoietic stem cell transplantation can be a curative treatment for a small group of patients, however MPN treatment is ... In MPNs, the neoplasm (abnormal growth) starts out as benign and can later become malignant. As of 2016, the World Health ... Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or ... Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as ...
Stem-cell transplantation offers possible cure, with survival rates of 50% at 3 years, although older patients do poorly. ... Fever, weight loss and splenomegaly should point to a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) rather than pure ... The success of bone marrow transplantation has been found to correlate with severity of MDS as determined by the IPSS score, ... HLA-matched allogeneic stem cell transplantation, particularly in younger (i.e. less than 40 years of age) and more severely ...
Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN (2015). "Hematolymphoid neoplasms associated with rearrangements of ... the aggressive chemotherapy and/or bone marrow transplantation used to treat aggressive leukemia may be required. While the ... Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ... a type of myeloproliferative neoplasm/myeloblastic leukemia not distinguished by eosinophilia; or c) T-lymphoblastic leukemia/ ...
... renal and cardiac transplantation, carcinoma of the head or neck, and other neoplasms (e.g., lung cancer, lymphoma, and ...
Topics included meningoencephalitis, cerebral atrophy, facial nerve paralysis, fibrous tissue neoplasm, lipoma, the anatomy of ... the endothelium, corneal transplantation, skin grafting, dental implants, hysterectomy, various types of cysts and "rare tumors ...
Secondary MPO deficiency, on the other hand, occurs in various clinical situations as a result of hematological neoplasm, ... disseminated cancers, some drugs, iron deficiency, lead intoxication, thrombotic disease, renal transplantation, severe ...
The myeloid neoplasms contain acute and chronic leukemias, myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms ( ... Hematopoietic stem cell transplantation remains the only curative treatment for CMML. However, due to the late age of onset and ... In 2001, the WHO Classification of Myeloid Neoplasms was published, classifying CMML into a new group of diseases, the ... Leukaemias are subdivided into lymphoid and myeloid neoplasms, depending on which bone marrow cells are cancerous. ...
"neoplasms"[MH] OR "transplantation"[ALL] OR "graft vs. host disease"[MH] OR "stem cell*"[ALL] OR "t-lymphocytes"[MH]) OR sloan- ... As a physician-scientist, van den Brink studies cancer immunotherapy with a special interest in bone marrow transplantation, T ... "Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation". N Engl J Med. 2020 Feb 27;382(9):822- ... "Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation ...
The incidence of MTS in patients with sebaceous neoplasms as high as 14 to 50%. Besides mutations in mismatch repair genes, Wnt ... there is evidence to suggest that solid organ transplantation may increase the risk of SGc up to 90 times. Others have observed ... SGc accounts for approximately 0.7% of all skin cancers and 0.2 to 4.6% of all malignant cutaneous neoplasms. Notable risk ... MTS is an autosomal dominant cancer syndrome characterized by multiple sebaceous and visceral neoplasms, the most common being ...
Most hepatectomies are performed for the treatment of hepatic neoplasms, both benign or malign. Benign neoplasms include ... Partial hepatectomies are also performed to remove a portion of a liver from a living donor for transplantation.[citation ... The most common malignant neoplasms (cancers) of the liver are metastases; those arising from colorectal cancer are among the ... typically cancer centres and transplantation centres).[citation needed] For optimal results, combination treatment with ...
King Fahad Specialist Hospital-Dammam continues to work closely with the Saudi Center for Organ Transplantation (SCOT), the ... chronic myeloproliferative neoplasms, and lymphomas: Hodgkin and non-Hodgkin types Bone marrow failure syndromes: aplastic ... High dose chemotherapy and stem cells rescue [autologous transplantation] for: myeloma, lymphoma, acute myeloid leukemia] ... of KFSH-D was established in 2008 to cover the need for organ transplantations in the Eastern Province and the kingdom. The ...
These include stem-cell transplantation and fecal microbiota transplantation. Cannabis[unreliable source?] has not been studied ... Bowel obstruction: mechanical or functional obstruction of the bowel, most commonly due to adhesions, hernias or neoplasms. ... A potential solution, albeit radical, is intestinal transplantation. This is only appropriate in the case of intestinal failure ... Bond, Geoffrey J.; Reyes, Jorge D. (November 2004). "Intestinal transplantation for total/near-total aganglionosis and ...
"Histology of Some Neoplasms and Non-Neo-plastic Lesions Found in Wild Mice Maintained Under Laboratory Conditions". JNCI: ... "Transplantation of Hepatomas in Mice1". JNCI: Journal of the National Cancer Institute. April 1955. doi:10.1093/jnci/15. ... "Histology of Some Neoplasms and Non-Neo-plastic Lesions Found in Wild Mice Maintained Under Laboratory Conditions" (1963), " ... "Transplantation of Hepatomas in Mice" (1955), "Morphology of Mammary Tumors in Mice" (1958), "Studies of the Mammary-Tumor ...
Further studies may indicate that this recent cancer chemotherapy regimen plus allogenic bone marrow transplantation in cases ... Vardiman JW, Harris NL, Brunning RD (2002). "The World Health Organization (WHO) classification of the myeloid neoplasms". ... of cases human stem cell transplantation, the probability of overall 4 year survival rate, probability of 4 year event-free ... allogenic rather than autologous stem cell bone marrow transplantation should be considered in non-DS-AMKL cases that have ...
Liver Transplantation Chapter 339: Diseases of the Gallbladder and Bile Ducts Section 4: Disorders of the Pancreas Chapter 340 ... Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Lung Transplantation Part 8: Critical Care Medicine Section 1: Respiratory Critical Care Chapter 293: Approach to the Patient ... Transplantation in the Treatment of Renal Failure Chapter 308: Glomerular Diseases Chapter 309: Polycystic Kidney Disease and ...
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. ... The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood. 2016 19;127(20):2375-90. ...
Comparison of Neoplasms in Six Sources of Rats Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed. ... Research applications include transplantation research, induced arthritis and inflammation, experimental allergic encephalitis ... The Lewis rat suffers from several spontaneous pathologies: first, they can suffer from high incidences of neoplasms, with the ... A 1972 study compared neoplasms in Sprague Dawley rats from six different commercial suppliers and found highly significant ...
Bone defects or fractures can occur in a number of ways, including trauma, neoplasm, osteoporosis, or congenital disorders. ... the most common treatment for which is allograft cornea transplantation. However, donor corneal grafts are in short supply and ...
One patient with ETV6-FLT3-related myeloid/lymphoid neoplasm obtained a short term remission on sunitinib and following relapse ... lymphoblastic leukemia with 2 among 3 family members moving rather quickly from chemotherapy to bone marrow transplantation and ... Reiter A, Gotlib J (February 2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10- ... myeloproliferative neoplasm (MPN), and acute myeloid leukemia (AML). (The presence of ETV6 gene mutations in myelodysplastic ...
Sertoli-Leydig cell tumour is part of the sex cord-stromal tumour group of ovarian neoplasms. These tumors produce both Sertoli ... Upon xenogenic transplantation, Sertoli cells have been shown to regain the ability to proliferate. Recently (2016), ... By treating spontaneously diabetic and obese mice with the transplantation of microencapsulated Sertoli cells in subcutaneous ... "Germ cell transplantation as a potential biotechnological approach to fish reproduction". Fish Physiology and Biochemistry. 39 ...
STEWART, SE; EDDY, BE; BORGESE, N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ... Ramqvist, T; Dalianis, T (August 2009). "Murine polyomavirus tumour specific transplantation antigens and viral persistence in ...
It can also involve bone marrow transplantation. Information on prognosis is limited by the rarity of the condition. Prognosis ... myeloproliferative neoplasms, chemotherapy for other cancers or exposure to toxins were defined as secondary AEL. These cases ... and in patients who had previously received chemotherapy for the treatment of a different neoplasm. Acute erythroid leukemia is ...
Allogeneic stem cell transplantation can induce durable remissions for heavily pre-treated patients. As of October 2010, there ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Autologous bone marrow transplantation is a treatment option. Zanubrutinib is indicated for the treatment of adults with ... Yang L, Wen B, Li H, Yang M, Jin Y, Yang S, Tao J (1999). "Autologous peripheral blood stem cell transplantation for ...
This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... prior organ transplantation, the decline in immunity that develops with aging, and/or cirrhosis of the liver due to hepatitis B ... List of hematologic conditions Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A ... and/or rarely of immune deficiency due to organ transplantation, hepatitis complicated by cirrhosis caused by hepatitis B or C ...
FGF23 is also overproduced by some types of tumors, such as the benign mesenchymal neoplasm phosphaturic mesenchymal tumor ... Transplantation. 17 (6): 958-61. doi:10.1093/ndt/17.6.958. PMID 12032180. Quarles LD (July 2003). "FGF23, PHEX, and MEPE ...
Autologous stem cell transplantation, using the recipient's own cells, is not curative.: 1458 Younger individuals, if at high ... Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... CLL is treated by chemotherapy, radiation therapy, biological therapy, or bone marrow transplantation. Symptoms are sometimes ...
In the United States it is also indicated for the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with ... Eligible participants were either not candidates for or have relapsed after allogeneic hematopoietic stem cell transplantation ... "FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement". U.S. Food and Drug ... for pemigatinib for the treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 ...
Uses of "malignant" in oncology include: Malignancy, malignant neoplasm and malignant tumor are synonymous with cancer ... Other risk factors include developing post-transplant malignancy which occurs subsequent to solid organ transplantations. ... American Journal of Transplantation. 10 (8): 1889-1896. doi:10.1111/j.1600-6143.2010.03181.x. PMID 20659094. S2CID 40192165. ...
Stem cell transplantation may be used if the disease recurs following standard treatment. Additional treatments such as ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... Moreover, patients undergoing a stem cell transplantation can develop a graft-versus-host disease (GvHD). It was evaluated ... Chemotherapies or stem cell transplantations may require a platelet transfusion to prevent bleeding. ...
2008). "Association of four DNA polymorphisms with acute rejection after kidney transplantation". Transpl. Int. 21 (9): 879-91 ... been identified as an intracellular target of the natural product sanglifehrin A This gene is up-regulated in some neoplasms, ... The Journal of Heart and Lung Transplantation. 29 (5): 509-516. doi:10.1016/j.healun.2009.11.602. PMID 20061166. Sombogaard F, ... a 2-year follow-up in kidney transplantation". Clin. Pharmacol. Ther. 83 (2): 328-35. doi:10.1038/sj.clpt.6100300. PMID ...
Autologous transplantation continues to be used as a component of therapy for a number of other hematologic malignancies. The ... A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951. PMID 14850976. Li, MC; Hertz ... This approach, termed autologous bone marrow transplantation, was initially thought to be of benefit to a wide group of ... However, rigorous studies have failed to confirm this benefit, and autologous transplantation is no longer widely used for ...
An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation". The ... who are immune-deficient due to HIV/AIDS or immunosuppressing anti-rejection drug therapy following solid organ transplantation ...
March 1997). "Factors predicting morbidity following hematopoietic stem cell transplantation". Bone Marrow Transplantation. 19 ... Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... Bone Marrow Transplantation. 37 (5): 499-502. doi:10.1038/sj.bmt.1705262. PMID 16415895. Suzuki A, Nakauchi H, Taniguchi H ( ... Transplantation. 78 (4): 516-23. doi:10.1097/01.TP.0000128854.20831.6F. PMID 15446309. S2CID 84476256. Valente T, Junyent F, ...
Over 100 years later, the only available curative, renal replacement therapy for CKD is kidney transplantation. However, many ... such as osteoporosis or underlying neoplasm. Analogous to vertebroplasty, the purpose of sacroplasty is to provide ...
Before transplantation, the organ donor was deemed to have no signs of cancer upon medical examination. Later, the organ ... Frierman EM, Andrews JD (February 1976). "Occurrence of hematopoietic neoplasms in Virginia oysters (Crassostrea virginica)". ... In humans, a significant fraction of Kaposi's sarcoma occurring after transplantation may be due to tumorous outgrowth of donor ... American Journal of Transplantation. 18 (7): 1810-1814. doi:10.1111/ajt.14766. PMID 29633548. Muehlenbachs A, Bhatnagar J, ...
Fuchs EJ (June 2015). "HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide ... Myeloproliferative neoplasms, including acute leukemia, non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 ... Or-Geva N, Reisner Y (March 2016). "The evolution of T-cell depletion in haploidentical stem-cell transplantation". British ... Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L (April 2016). "Haploidentical bone marrow and stem cell transplantation: ...
"Serum thymidine-kinase and cytomegalovirus-specific antibodies after renal transplantation". Transplantation Proceedings. 20 (3 ... Lipkin M, Deschner E, Troncale F (1970). "Cell differentiation and the development of colonic neoplasms". CA: A Cancer Journal ... "Biochemical measure of the volume doubling time of human pulmonary neoplasms". Cancer. 55 (7): 1530-5. doi:10.1002/1097-0142( ...
Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment ... Léger, Chantal S.; Nevill, Thomas J. (11 May 2004). "Hematopoietic stem cell transplantation: a primer for the primary care ... In chemotherapy as a conditioning regimen in hematopoietic stem cell transplantation, a study of people conditioned with ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ...
2008). 'Metabolic Management - Organ Procurement and Preservation For Transplantation. New York: Landes Bioscience Springer. ... Carcinogenesis and Neoplasm) and reference). Furthermore, the ability of HRR to accurately and efficiently repair double-strand ...
"Expertscape: Pancreatic Neoplasms, November 2018". expertscape.com. November 2018. Retrieved 2018-11-26. Scholia has an author ... "Director of the Clinic for General, Visceral and Transplantation Surgery". Heidelberg surgery hospital. Retrieved 22 March 2012 ... Visceral and Transplantation Surgery at Heidelberg University Hospital. Since 2003 he is managing medical director of the ... Neoplasms of the Pancreas. Karger 2004, ISBN 3-8055-7613-7 Chronic Pancreatitis. Wiley-Blackwell 2002, ISBN 0-632-06399-8 ...
μ Heavy chain disease presents with a picture of a lymphoid neoplasm resembling either chronic lymphocytic leukemia or small ... or symptomatic disseminated disease have been treated with chemotherapy often followed by autologous stem-cell transplantation ... or other B cell-associated neoplasm, that has developed, often in a stepwise manner, from their MGUS precursors. The clinical ... of patients lack any evidence of a lymphoplasmacytic neoplasm. A majority of the latter patients have an autoimmune disease or ...
Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Urologe (in German). 10 (3): 117-9. ... A historical overview". Hair Transplantation, Third Edition. Taylor & Francis. pp. 1-33. ISBN 978-0-8247-9363-0. Shamim Tejani ...
Adenomas, composed of heterogeneous neoplasms, may occur individually or in multiples. Estimates on the rate of conversion of a ... Several children with advanced hepatic complications have improved after liver transplantation. Additional problems reported in ...
MCLORNAN, Donal P et al. Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, ... Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective ... Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982). Citation. (ISO format) ... Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype ...
Plasma cell neoplasms in U.S. solid organ transplant recipients Cite CITE. Title : Plasma cell neoplasms in U.S. solid organ ... Title : Risk of myeloid neoplasms after solid organ transplantation Personal Author(s) : Morton, Lindsay M.;Gibson, Todd M.; ... SIRs were highest among younger individuals and varied by time since transplantation and organ type (Poisson regression P. ... Title : Risk of lymphoma subtypes after solid organ transplantation in the United States Personal Author(s) : Clarke, C A; ...
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. ...
YF vaccine is contraindicated for persons with primary immunodeficiencies, malignant neoplasms, and transplantation (127). ... malignant neoplasms, 5) transplantation, and 6) immune suppression or modulation attributable to current or recent radiation ... Live viral vaccines should be deferred in persons with a history of malignant neoplasm or transplantation until immune function ... solid organ transplant or hematopoietic stem cell transplant recipients within 2 years of transplantation, or persons whose ...
According to the registry of the International Society for Heart and Lung Transplantation, approximately 350-500 pediatric ... heart transplantation procedures are performed worldwide each year, representing about 12% of the total number of heart ... Heart transplantation in infants and children is now accepted therapy. ... By 1984, the medical field was again ready for infant transplantation. For the next 10 years, orthotopic heart transplantation ...
Malignant neoplasms. *Transplantation. *Immunosuppressive and immunomodulatory therapies. *Age 6-8 months. *Age ≥60 years ... This includes organ transplant patients and those with malignant neoplasms. See Chapter 5, Immunocompromised Travelers. ...
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (National Cancer Institute) Also in Spanish * Myelofibrosis (Mayo ... Bone Marrow Transplantation: MedlinePlus Health Topic (National Library of Medicine) Also in Spanish ... Treatment Option Overview (Chronic Myeloproliferative Neoplasms) (National Cancer Institute) Also in Spanish ... Treatment Option Overview (Myelodysplastic/Myeloproliferative Neoplasms) (National Cancer Institute) Also in Spanish ...
Kidney Neoplasms [‎5]‎. Kidney Transplantation [‎9]‎. Killer Cells, Natural [‎1]‎. Klebsiella [‎1]‎. ...
Neoplasm Transplantation * Signal Transduction * Tumor Burden Substances * FOXM1 protein, human * Forkhead Box Protein M1 ...
... of all these neoplasms. The remainder of the pathological spectrum includes benign and malignant cell types. ... Treatment of cardiac tumors by orthotopic cardiac transplantation. Semin Oncol. 1997 Oct. 24(5):534-9. [QxMD MEDLINE Link]. ... encoded search term (Primary Cardiac Neoplasms) and Primary Cardiac Neoplasms What to Read Next on Medscape ... Primary Cardiac Neoplasms Workup. Updated: Mar 16, 2023 * Author: Mary C Mancini, MD, PhD, MMM; Chief Editor: Eric H Yang, MD ...
History of haploidentical allogeneic stem cell transplantation. *Subjects both with urinary outflow obstructions and on ... TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms. The safety and scientific validity of this study is ... The Phase I dose escalation part will establish the MTD/RP2D in subjects with high risk myeloid and lymphoid neoplasms, a total ... in Subjects With High Risk Myeloid and Lymphoid Neoplasms. ...
Kidney Neoplasms [‎5]‎. Kidney Transplantation [‎9]‎. Killer Cells, Natural [‎1]‎. Klebsiella [‎1]‎. ...
Skin neoplasms. *Stem cell transplantation. Contact Information. *Appointments617-732-8821. *Office Phone Number617-732-8821 ...
"The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation". N. Engl. J. Med. 332 (1 ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... p. Neoplasm. ISBN 978-0781733908. .. *^ "II Neoplasms". International Statistical Classification of Diseases and Related Health ... The term neoplasm is a synonym of tumor. Neoplasia denotes the process of the formation of neoplasms/tumors, and the process is ...
Neoplasm Transplantation. 1. 2007. 2191. 0.010. Why? Gadolinium. 1. 2007. 908. 0.010. Why? ...
By contrast, the cases of pure plasma cell neoplasm (23%) had similar rates of t(11;14) compared to non-IgM-associated ... The largest series of autologous stem cell transplantation in 38 patients44 included 58% who had received prior therapy and the ... The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-2390. https ... The best outcomes have been achieved by autologous stem cell transplantation, with more than 90% achieving a hematologic ...
Neoplasms/pathology*. *Prostatic Neoplasms/pathology. *Transplantation, Heterologous. *Zebrafish. PubMed. 22347456 Full text @ ...
Undifferentiated neoplasm diagnosis. *Renal pathology (glomerulopathies, transplantation). *Neuromuscular pathology. *Metabolic ...
Uterine Neoplasms. Hematopoietic Cell Transplantation. March. Smoking Cessation. Prostate Cancer Early Detection. ...
NK Cells, Their Receptors, Transplantation and Cancer Th. Miller, J. S., Cooley, S. A., Ho, Y., Le, C. T., Luo, X., Tolar, J., ... Enhancing the Safety of Allogeneic Transplantation. Weisdorf, D. J., Arora, M., Brunstein, C. G., McClune, B. L. & Wagner, J. E ... Enhancing the Safety of Allogeneic Transplantation. Weisdorf, D. J., Arora, M., Brunstein, C. G., McClune, B. L. & Wagner, J. E ... Project 2: (Bhatia/Bhatia) Therapy-related leukemia following autologous transplantation for lymphoma. Weisdorf, D. J. & Arora ...
In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 7, 07.2019, p. 1424-1431.. Research output: Contribution to ... High-dose busulfan (BU) followed by high-dose cyclophosphamide (CY) before allogeneic hematopoietic cell transplantation (HCT) ... N2 - High-dose busulfan (BU) followed by high-dose cyclophosphamide (CY) before allogeneic hematopoietic cell transplantation ( ... AB - High-dose busulfan (BU) followed by high-dose cyclophosphamide (CY) before allogeneic hematopoietic cell transplantation ( ...
Assessing Race-Related Outcomes in Hematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms. ...
... for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications ... Hematologic Neoplasms Hematologic Diseases Severe Aplastic Anemia Pediatric Adult , Myelodysplastic Syndromes (MDS) , A ... Aplastic Anemia, Aplastic Anemia, Anemia; Non-Small-Cell Lung Cancer, Myelodysplastic Syndromes (MDS), Hematologic Neoplasms ... A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in ...
Central Nervous System Neoplasms / therapy* * Combined Modality Therapy * Disease-Free Survival * Febrile Neutropenia / ... Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results ... or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma ( ...
Myeloproliferative neoplasms and recurrent thrombotic events in patients undergoing liver transplantation for Budd-Chiari ... Hepatic venous and inferior vena cava morphology no longer a barrier to living donor liver transplantation for Budd-Chiari ... Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007 Sep. 13(9): ... Eighteen years of liver transplantation experience in patients with advanced Budd-Chiari syndrome. Liver Transpl. 2008 Feb. 14( ...
Novel Diagnostics in Transplantation. Ansari, MJ. & Strom, TB., 2010, Chronic Kidney Disease, Dialysis and Transplantation. ... Thorp, E. B., Stehlik, C. & Ansari, M. J., Feb 21 2015, In: Current opinion in organ transplantation. 20, 1, p. 37-42 6 p.. ... Yuan, X., Ansari, M. J. & Sayegh, M. H., Feb 1 2006, In: Current opinion in organ transplantation. 11, 1, p. 24-29 6 p.. ... Abadja, F., Sarraj, B. & Ansari, M. J., Feb 2012, In: Current opinion in organ transplantation. 17, 1, p. 8-14 7 p.. Research ...
... is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence ... With the exception of few cases eligible to bone marrow transplantation, no known treatment is able to alter the natural course ... Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both ... PMF is a myeloproliferative neoplasm frequently complicated by transfusion-dependent anemia. ...
myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) A Case Series of Post-Transplantation Cyclophosphamide in ... Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation aplastic ... myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable ... Unrelated Donor Hematopoietic Cell Transplantation for Aplastic Anemia Jun 2020 ...
  • Current opinion in organ transplantation. (northwestern.edu)
  • I worked for 15 year for two global medical associations, the International Society of Nephrology (ISN) and the European Society for Organ Transplantation (ESOT). (segantini.blog)
  • Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. (unige.ch)
  • Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. (unige.ch)
  • Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. (hindawi.com)
  • Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U): More Than Just a 'Catch-All' Term? (aamds.org)
  • Splenomegaly or hepatosplenomegaly may indicate an overlapping myeloproliferative neoplasm. (cancer.gov)
  • To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). (nih.gov)
  • Allogenic haematopoietic stem cell transplantation (allo-HSCT) is currently not considered. (medicaljournals.se)
  • High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. (elsevier.com)
  • High-dose chemotherapy with hematopoietic stem-cell transplantation (HDC/HSCT) has been extensively studied as a potential treatment for breast cancer. (elsevier.com)
  • Dive into the research topics of 'High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. (elsevier.com)
  • To date, allogenic stem cell transplantation remains the only curative option for MPNs but it is often not considered due to age-related co-morbidities and high transplant-associated mortality rates. (biomedcentral.com)
  • Background: Haematopoietic stem cell transplantation constitutes a therapeutic choice for the treatment of a number of paediatric diseases. (hjn.gr)
  • Marta Sobas of Medical University of Wroclaw, Poland: "The decision to perform stem cell transplantation in AML patients who achieved the first complete remission is based on the risk-benefit ratio. (harmony-alliance.eu)
  • Patients with a low to intermediate risk of relapse are not classical candidates for stem cell transplantation. (harmony-alliance.eu)
  • For lymphoid neoplasms, e.g. lymphoma and leukemia , clonality is proven by the amplification of a single rearrangement of their immunoglobulin gene (for B cell lesions) or T cell receptor gene (for T cell lesions). (wikipedia.org)
  • 1 IgM MGUS is a pre-malignant condition for non-Hodgkin lymphomas, mostly Waldenström macroglobulinemia (WM), chronic lymphocytic lymphoma, and plasma cell neoplasms. (haematologica.org)
  • We conclude that malignant tumors occurring after transplantation are often advanced and that lymphoma induced by cyclosporine has characteristic features. (elsevier.com)
  • Dr. Nishihori's clinical interests include autologous and allogeneic hematopoietic cell transplantation as well as immunotherapeutic approaches for multiple myeloma, plasma cell dyscrasias, amyloidosis, malignant lymphoma, acute and chronic leukemias, myelodysplastic syndrome, myelofibrosis and myeloproliferative disorders. (moffitt.org)
  • Lymphoma is a malignant neoplasm that develops in the lymph nodes. (bvsalud.org)
  • Biology of Blood and Marrow Transplantation , 25 (7), 1424-1431. (elsevier.com)
  • Dr. Nishihori is an assistant member in the Blood and Marrow Transplantation Department at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida. (moffitt.org)
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is primarly a disease of the elderlies with an overall infaust prognosis. (medicaljournals.se)
  • Based on the clinico-pathological correlation the diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) was retained. (medicaljournals.se)
  • 2) to establish a possible relationship between clinical and laboratory findings in the context of Polycythemia Vera (PV), Essential Thrombocytemia (ET), Primary Myelophibrosis (PMF) and Myeloproliferative Neoplasms unclassifiable (MPN-U). (scirp.org)
  • Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. (unige.ch)
  • This review introduces various methods and strategies to improve ovarian tissue cryopreservation and transplantation outcomes, to help patients and clinicians choose the best option when considering the potential complexity of a patient's situation. (dundee.ac.uk)
  • Currently, chemotherapy and liver transplantation have improved outcomes. (bvsalud.org)
  • Abdel-Rahman O , Ghosh S , Morrish D . Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms. (wjgnet.com)
  • High-dose busulfan (BU) followed by high-dose cyclophosphamide (CY) before allogeneic hematopoietic cell transplantation (HCT) has long been used as treatment for hematologic malignancies. (elsevier.com)
  • List the important advances in pretransplantation risk assessment and transplant techniques for hematopoietic cell transplantation in patients with myeloid malignancies. (clevelandclinicmeded.com)
  • Dr. Zeeshan Ansar participated in a virtual activity on, ' The 1st Congress on Myeloproliferative Neoplasms controversies and debates ', European board for accreditation in Haematology- EBAH, November 11-12, 2022. (aku.edu)
  • Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. (cdc.gov)
  • INTRODUCTION: The NRF is the organization fnancing in Uruguay the treatment of the three renal replacement techniques (RRT): kidney transplantation (TxR), peritoneal dialysis (PD) and hemodialysis (HD). (bvsalud.org)
  • Tumor diameter on cross sectional imaging remains the key parameter for treatment de cisions in renal neoplasms, with nephrectomy being preferred for larger lesions. (sjkdt.org)
  • Introduction: Renal transplantation is considered the treatment of choice for patients with end-stage renal disease (ESRD) and is associated with decreased mortality when compared to dialysis methods. (unifesp.br)
  • Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study. (ebsco.com)
  • The Phase I dose escalation part will establish the MTD/RP2D in subjects with high risk myeloid and lymphoid neoplasms, a total of 3 disease entities. (clinicaltrials.gov)
  • Secondary or metastatic neoplasms arise from hematologic spread of the originating tissue. (medscape.com)
  • The role of electron microscopy in characterization of uncommon epithelial pulmonary neoplasms, metastatic neoplasms to and from lung and other tumors, including mesenchymal neoplasms. (uab.edu)
  • Secondary neoplasm refers to any of a class of cancerous tumor that is either a metastatic offshoot of a primary tumor, or an apparently unrelated tumor that increases in frequency following certain cancer treatments such as chemotherapy or radiotherapy . (wikipedia.org)
  • Spectral Doppler ultrasonographic waveform of the right hepatic artery in a 60-year-old man, 8 years after orthotopic liver transplantation. (medscape.com)
  • A-1: Magnetic resonance angiogram in a transplantation patient with hepatic artery thrombosis. (medscape.com)
  • Methodology: a retrospective survey of medical records of patients aged up to 18 years with a diagnosis of primary malignant hepatic neoplasm between 2012 and 2020, carried out in the largest exclusively pediatric hospital in Brazil. (bvsalud.org)
  • However, the results and survival have improved with the advancement of chemotherapy, surgical technique, and liver transplantation. (bvsalud.org)
  • Bone marrow transplantation. (bvsalud.org)
  • Ciclosporin, an immunosuppressant, is used extensively in the prevention and treatment of graft-versus-host reactions in bone-marrow transplantation and to prevent the rejection of kidney, heart, and liver transplants. (who.int)
  • Histopathology, the standard method to assess BM in hematologic malignancies such as myeloproliferative neoplasms (MPNs), suffers from notable limitations in both research and clinical settings. (jci.org)
  • Myeloproliferative neoplasms (MPNs) are a group of chronic clonal haematopoietic disorders. (biomedcentral.com)
  • High-throughput DNA sequence analysis was used to screen for TET2 mutations in peripheral blood derived DNA from 97 patients with BCR-ABL-negative-myeloproliferative neoplasms (MPNs). (scirp.org)
  • [ 3 ] . An increasing number of orthotopic and living-donor liver transplantations are being performed to salvage patients with otherwise incurable end-stage liver disease (ESLD). (medscape.com)
  • Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. (edu.au)
  • OBJECTIVE: To establish a series of clinically relevant orthotopic transplantation models of human pancreatic adenocarcinoma from both cell lines and primary tumors under uniform experimental conditions. (edu.au)
  • Dive into the research topics of 'Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. (edu.au)
  • The armamentarium for managing HCC is wide and includes surgical resection, orthotopic liver transplantation (OLT), ablative techniques using ethanol (percutaneous ethanol injection, PEI), microwave (MWA) or radiofrequency (RFA), catheter-directed transarterial chemoembolization (TACE) or radioembolization (TARE), external beam radiation therapy in the form of stereotactic body radiation therapy (SBRT) or proton beam therapy (PBT), systemic targeted small molecule tyrosine kinase inhibitors, check-point inhibitor immunotherapy and investigational agents. (intechopen.com)
  • In modern English, tumor is used as a synonym for neoplasm (a solid or fluid-filled cystic lesion that may or may not be formed by an abnormal growth of neoplastic cells) that appears enlarged in size. (wikipedia.org)
  • [12] [13] Some neoplasms do not form a tumor - these include leukemia and most forms of carcinoma in situ . (wikipedia.org)
  • El Sarcoma Embrionario Indiferenciado, como tumor primario hepático es una patología que se presenta en la edad pediátrica, en adultos los casos son raros y representan aproximadamente el 0.2% de los tumores hepáticos primarios. (bvsalud.org)
  • El tratamiento curativo consiste en la resección quirúrgica del tumor y, en casos de irresecabilidad o afectación extrahepática, se justifica considerar radioquimioterapia paliativa y asociarla o no a cirugía. (bvsalud.org)
  • Heart transplantation may be appropriate in those instances in which the benign tumor is too large to resect. (medscape.com)
  • Lee et al retrospectively enrolled 75 patients who had undergone liver transpalantation and found that although MDCT in the late period should be interpreted with caution in patients with suspected biliary complication, MDCT is a reliable diagnostic technique for the identification of early and late abdominal complications after liver transplantation. (medscape.com)
  • Ovarian tissue cryopreservation and transplantation is a promising option for fertility preservation in pre-pubertal girls and adult patients with cancer who require immediate treatment, or who are not eligible to undergo ovarian stimulation. (dundee.ac.uk)
  • Skin cancer is the most frequently described neoplasm among OTRs, whereas squamous cell carcinoma (SCC) is very often declared to be the most frequently occurring cancer among those patients. (termedia.pl)
  • [ 4 ] Doppler ultrasonography plays an important role in the postoperative management of liver transplantation. (medscape.com)
  • ABSTRACT Introduction: liver tumors are rare neoplasms in childhood (1-2%), and about 2/3 are malignant. (bvsalud.org)
  • Only one patient was treated with surgery without neoadjuvant therapy, another one underwent transplantation like the first treatment, and another 2 required liver transplantation as a rescue. (bvsalud.org)
  • He is accredited by the American Society of Transplant Surgeons and Ministry of Health in liver, kidney and pancreas transplantation. (annals.edu.sg)
  • He is a thought leader in the field for his clinical and academic work on laparoscopic and robotic surgery, liver cancers and pancreatic cystic neoplasms. (annals.edu.sg)
  • The neoplasms of the skin, vulva, uterine cervix, and urinary bladder were low-grade malignant tumors. (elsevier.com)
  • Although the overall incidence of primary cardiac neoplasms is low (0.0001-0.5% in autopsy series), these tumors provide unique diagnostic and therapeutic challenges. (medscape.com)
  • My scientific focus is leukemia, specifically myeloproliferative neoplasms (MPN) including CML, chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF). (utah.edu)
  • Cystic nephroma (CN) is a rare benign neoplasm of kidney with excellent prog nosis. (sjkdt.org)
  • See the images below of transplantation complications. (medscape.com)
  • This Philadelphia negative-myeloproliferative neoplasms (MPN) are a spectrum of clonal disorders of the hematopoietic system characterized by overproduction of mature blood elements, a trend to thrombotic and/or hemorrhagic complications with variable rates of transformation to secondary myelofibrosis and acute leukemia [1]. (scirp.org)
  • [7] Malignant neoplasms are also simply known as cancers and are the focus of oncology . (wikipedia.org)
  • A neoplasm can be benign , potentially malignant, or malignant ( cancer ). (wikipedia.org)
  • Malignant neoplasms are commonly called cancer. (wikipedia.org)
  • Rarely there can be a metastatic neoplasm with no known site of the primary cancer and this is classed as a cancer of unknown primary origin . (wikipedia.org)
  • Effective multidisciplinary oncofertility strategies, involving the inclusion of a highly skilled and experienced oncofertility team that considers cryopreservation methods, thawing processes and devices, surgical procedures for transplantation, and advances in technologies, are necessary to provide high-quality care to a cancer patient. (dundee.ac.uk)
  • His thesis from 1938 was on transplantation of cancer from one animal species to another after Xray exposure. (who.int)
  • His publication series in 5 volumes "Statistical studies in malignant neoplasms" still stand as a milestone in cancer epidemiology with observations and analysis and literature review up to 1977. (who.int)
  • benign neoplasms , in situ neoplasms , malignant neoplasms , and neoplasms of uncertain or unknown behavior. (wikipedia.org)
  • The primary objective of this study is to examine the incidence of neutrophil recovery of greater than or equal to 500/mm(3) after cord blood transplantation in a multi-institution setting using CBUs that are not Food and Drug Administration (FDA) licensed. (centerwatch.com)
  • Primary neoplasms may arise from endocardium, valvular structures, primitive tissue rests, and the conduction system. (medscape.com)
  • Potentially-malignant neoplasms include carcinoma in situ . (wikipedia.org)
  • This closed cryopreservation/defrost system allows for sterility in addition to increased viability, recovery and safety of tissues that can be used for in vitro culture or surgical transplantation. (cancer.gov)